title: Feasibility of 2-deoxy-2-[18F]fluoro-D-glucose- A85380-PET for imaging of human cardiac nicotinic acetylcholine receptors in vivo.
abstract: Nicotinic acetylcholine receptors mediate the parasympathetic autonomic control of cardiac function. Aim of this study was the assessment of cardiac nicotinic acetylcholine receptor distribution with a novel (alpha4beta2) nicotinic acetylcholine receptor PET ligand (2-deoxy-2- [18F]fluoro-D-glucose-A85380) in humans. Five healthy volunteers without cardiac disease and six patients with either Parkinson's disease or multiple system atrophy without additional overt cardiac disease were evaluated with 2-deoxy-2-[18F]fluoro-D-glucose-A85380 PET-imaging to assess the cardiac parasympathetic innervation and the putative impact of both disorders. 2-deoxy-2- [18F]fluoro-D-glucose-A85380 whole body PET-scans were performed on a Siemens PET/CT biograph(TM) 75.4 min +/- 6.7 after i.v. injection of 371.2 +/- 58.1 MBq. Average count rate density of left ventricle ROI's and a standard ROI in the right lung were measured within three consecutive slices of 10.0 mm thickness. Heart-to-lung ratios were calculated in each volunteer and patient. Tracer uptake in the left ventricle could be measured in all of the five volunteers and the six patients. Heart-to-lung ratios in the volunteer group were not different from patients suffering from Parkinson's disease or MSA (3.2 +/- 0.5 vs 3.2 +/- 0.8 and 2.96+/-0.7, mean +/- SD), respectively. Human cardiac nicotinic acetylcholine receptors can be visualized and measured by 2-deoxy-2- [18F]fluoro-D-glucose-A85380 PET scans both in cardiac-healthy subjects and patients suffering from Parkinson's disease or multiple system atrophy. The heart- as well as the lung-tracer uptake was almost constant throughout all subjects leading to a good target-to-background ratio. These first results suggest no impact of either PD or MSA on cardiac nicotinic acetylcholine receptors.
authors.affiliation: University of Bonn, Department of Nuclear Medicine, Sigmund-Freud-Str. 25, 53105 Bonn, Germany. jan.bucerius@ukb.uni-bonn.de
authors.forename: Jan
authors.initials: J
authors.lastname: Bucerius
authors.forename: Alexius Y
authors.initials: AY
authors.lastname: Joe
authors.forename: Jörn
authors.initials: J
authors.lastname: Schmaljohann
authors.forename: Daniela
authors.initials: D
authors.lastname: Gündisch
authors.forename: Martina
authors.initials: M
authors.lastname: Minnerop
authors.forename: Hans-Jürgen
authors.initials: HJ
authors.lastname: Biersack
authors.forename: Ullrich
authors.initials: U
authors.lastname: Wüllner
authors.forename: Michael J
authors.initials: MJ
authors.lastname: Reinhardt
mesh_terms: D000368:Aged; D005240:Feasibility Studies; D005260:Female; D019788:Fluorodeoxyglucose F18; D006321:Heart / Q000294:innervation*; D006352:Heart Ventricles / Q000000981:diagnostic imaging / Q000378:metabolism; D006801:Humans; D008297:Male; D008875:Middle Aged; D019578:Multiple System Atrophy / Q000000981:diagnostic imaging* / Q000378:metabolism; D009206:Myocardium / Q000378:metabolism; D010300:Parkinson Disease / Q000000981:diagnostic imaging* / Q000378:metabolism; D049268:Positron-Emission Tomography; D019275:Radiopharmaceuticals; D011978:Receptors, Nicotinic / Q000378:metabolism*
chemical_list: D019275:Radiopharmaceuticals; D011978:Receptors, Nicotinic; D019788:Fluorodeoxyglucose F18